Ganaxolone for Irritability in Children With Autism
Part of Mental health clinical trials.
This study tests whether a medication called ganaxolone can reduce irritability and aggressive behaviors in children ages 5–17 with autism. Ganaxolone works on the brain in a way that may help calm emotional outbursts and frustration.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 5 and 17 years old
- Confirmed diagnosis of autism spectrum disorder
- Significant irritability or aggressive behavior (scored on a standardized checklist)
- Stable medications and therapies for at least 2–4 weeks before starting
- Able to attend in-person visits near Stanford University and complete brain scans
- A trusted adult (parent, caregiver) available to observe and report on the child's behavior throughout the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether N-acetylcysteine, a medicine taken by mouth, can improve autism-related restricted and repetitive behaviors in children. It looks at children who are showing at least moderate severity in these behaviors and may involve brain testing for safety reasons.
This Phase 2 study tests whether a single dose of N-acetylcysteine can improve “restricted and repetitive behaviors” in children with autism. It’s meant for kids who are stable and still in early puberty stages.
This Phase 2 study tests zolpidem (a sleep medicine) to help children with autism sleep better. It will check sleep changes using sleep testing and to confirm zolpidem is safe for this age group.
This trial tests an experimental gene therapy (VGN-Ex05e) for children and teens with autism who have severe self-injury or aggression that hasn't improved with other treatments. The therapy is given as a one-time injection into a specific brain area. The goal is to see if it reduces these dangerous behaviors.
This trial tests whether buspirone, a medication that helps with anxiety, can reduce anxiety in children and teens with autism. It is a 12-week study where participants receive buspirone or a placebo (a pill with no medicine) to see if it improves anxiety symptoms.
This Phase 2 study tests CBDV, a form of cannabis-based medicine, compared with placebo (dummy medicine) in children with autism who have significant irritability and social challenges. It aims to see whether CBDV can improve behavior and overall symptom severity safely over the study period.
Hear when a new Autism in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.